Zinc of Ireland Limited
AASX:ZMI0.02
AUD
+0.00
(-5.56%)
Zinc of Ireland Limited
ASX:ZMI
(Australian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Zinc of Ireland NL (ASX: ZMI) operates as a mineral exploration and development company focused on zinc-lead deposits in the Republic of Ireland and Western Australia. The company explores for high-grade Irish-Type zinc projects, including its flagship Kildare Project comprising contiguous prospecting licenses covering approximately 240 square kilometers located 40 kilometers southwest of Dublin within the Rathdowney base metal trend; the Rathdowney Trend portfolio with 81 prospecting licenses either granted or under offer; the Mt Clere Project in Western Australia featuring the Robin 21 anomaly with broad sulphide mineralization intersections; and the Earaheedy Basin exploration license EL38/3624 granted in November 2021 for a five-year term. Zinc of Ireland also pursues orogenic gold mineralization through its Murchison Gold Project exploration license application ELA 21/230. Incorporated in 2007 and headquartered in Subiaco, Australia, the company conducts operations primarily in Ireland and Australia, targeting zinc, lead, copper, silver and gold deposits with inferred resources at Kildare's McGregor and Shamrock zones. In recent developments, Zinc of Ireland completed a capital raising on 22 August 2024 to fund ongoing activities; reported steady progress in the quarter ending September 2025 including gravity geophysical surveys at Kildare, successful drilling at Mt Clere, and Rathdowney tenure refinement by surrendering less prospective licenses; issued 265,655,351 ordinary shares via a pro rata securities offer; advanced 2025 quarterly results with assays pending and 2026 fully funded for district-wide development; and held its 2025 annual general meeting securing shareholder approval for re-elections, share issues, and a 10% placement facility.